A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT00050778 · COMPLETED

Trial details

NCT number: NCT00050778
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Sclerosis, Relapsing-Remitting

Start date: 2002-12-01
Primary completion: 2007-09-01
Enrollment: 334

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.